secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-08-29T23:59:59+00:00
Accession:  0001437749-25-027975
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech raises $6.0M via warrant exercise; issues 64.9M new warrants at $0.55
--------------------------------------------------------------------------------

- Gross proceeds of $6.0M from immediate cash exercise of 16.2M existing warrants at $0.37/share.
- Issues new unregistered Series F warrants to purchase up to 64.9M shares at $0.55, exercisable upon shareholder approval.
- New warrants have 5-year term, anti-dilution protection with a floor of $0.11, and a 4.99%/9.99% beneficial ownership cap.
- Company to file resale registration statement by Sep 26, 2025; use proceeds for working capital.
- Transaction closed Aug 28, 2025; Roth Capital Partners acted as financial advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925027975/0001437749-25-027975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925027975/mbrx20250828_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer